Neuberg Diagnostics forms JV with Sehgal Path Lab to expand haemato-oncology segment

29th April, 2024

The collaboration will see Sehgal Path Lab rebranded as Neuberg Sehgal Path Lab

image credit- shutterstock

image credit- shutterstock

Neuberg Diagnostics, one of the top 4 pathology laboratory chains in India, with more than 200 labs and 2000+ collection centres and having a presence in India, South Africa, UAE, and the USA has joined forces with Sehgal Path Lab in a strategic joint venture aimed at enhancing the Haemato-Oncology segment.

Sehgal Path Lab has garnered acclaim for its exceptional services in the field of haematology. The collaboration will see Sehgal Path Lab rebranded as Neuberg Sehgal Path Lab soon, aligning with Neuberg's commitment to delivering superior diagnostic solutions.

Dr Kunal Sehgal, a nationally acclaimed haematopathologist, will continue to lead as the Managing Director and Chief Pathologist of the joint venture (JV).

Dr Sehgal's expertise and leadership will be instrumental in driving the expansion of the laboratory into a Global Centre of Excellence for the Haemato-Oncology segment, with a specific focus on Flow Cytometry Assays, Bone Marrow examination and developing a Myeloma Speciality Laboratory.

Speaking about the Joint venture, Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said, “With four entities based in Mumbai and AG Diagnostics, a Neuberg subsidiary, in Pune, Neuberg has significantly bolstered its presence in Maharashtra. This strategic consolidation reaffirms Neuberg's leadership position in Karnataka, Gujarat, Tamil Nadu, and Madhya Pradesh, while paving the way for further growth and innovation in Maharashtra's healthcare landscape."

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer